Nifty
Sensex
:
:
19664.70
65945.47
-9.85 (-0.05%)
-78.22 (-0.12%)

Pharmaceuticals & Drugs - Global

Rating :
70/99

BSE: 524404 | NSE: MARKSANS

106.05
26-Sep-2023
  • Open
  • High
  • Low
  • Previous Close
  •  106.35
  •  106.50
  •  103.75
  •  105.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1140374
  •  1202.65
  •  122.50
  •  45.40

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 4,801.27
  • 17.44
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 4,127.90
  • 0.47%
  • 2.64

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 43.85%
  • 2.30%
  • 32.37%
  • FII
  • DII
  • Others
  • 14.9%
  • 2.79%
  • 3.79%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.39
  • 13.12
  • 10.41

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.53
  • 20.76
  • -0.02

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.99
  • 28.35
  • 4.12

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.33
  • 11.85
  • 11.92

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.01
  • 2.20
  • 2.50

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 12.92
  • 7.69
  • 7.61

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Net Sales
500.03
433.77
15.28%
485.98
418.04
16.25%
479.83
362.63
32.32%
452.56
361.20
25.29%
Expenses
398.07
360.91
10.30%
376.43
354.40
6.22%
403.19
304.83
32.27%
372.30
301.10
23.65%
EBITDA
101.97
72.86
39.95%
109.55
63.64
72.14%
76.64
57.80
32.60%
80.27
60.10
33.56%
EBIDTM
20.39%
16.80%
22.54%
15.22%
15.97%
15.94%
17.74%
16.64%
Other Income
10.10
16.50
-38.79%
11.01
15.34
-28.23%
17.65
12.06
46.35%
14.15
8.57
65.11%
Interest
1.58
1.80
-12.22%
2.44
5.03
-51.49%
2.35
0.95
147.37%
2.54
1.50
69.33%
Depreciation
13.66
11.12
22.84%
13.94
21.36
-34.74%
12.74
8.56
48.83%
14.05
7.39
90.12%
PBT
96.83
76.45
26.66%
104.17
52.60
98.04%
79.20
60.35
31.23%
77.83
59.78
30.19%
Tax
26.39
16.26
62.30%
21.46
22.95
-6.49%
16.90
12.08
39.90%
17.71
13.49
31.28%
PAT
70.44
60.18
17.05%
82.71
29.65
178.95%
62.31
48.27
29.09%
60.12
46.29
29.88%
PATM
14.09%
13.87%
17.02%
7.09%
12.98%
13.31%
13.28%
12.81%
EPS
1.52
1.46
4.11%
1.81
0.69
162.32%
1.57
1.20
30.83%
1.52
1.13
34.51%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
1,918.40
1,852.14
1,490.84
1,376.18
1,134.21
1,000.07
912.69
767.16
893.33
796.69
630.00
Net Sales Growth
21.75%
24.23%
8.33%
21.33%
13.41%
9.57%
18.97%
-14.12%
12.13%
26.46%
 
Cost Of Goods Sold
949.29
921.36
716.81
595.05
567.83
498.01
523.13
458.74
509.69
445.44
367.93
Gross Profit
969.11
930.78
774.02
781.13
566.38
502.07
389.57
308.42
383.63
351.25
262.07
GP Margin
50.52%
50.25%
51.92%
56.76%
49.94%
50.20%
42.68%
40.20%
42.94%
44.09%
41.60%
Total Expenditure
1,549.99
1,512.82
1,231.96
1,036.58
941.96
867.92
834.31
734.24
760.91
620.86
516.04
Power & Fuel Cost
-
24.50
18.59
16.42
14.38
14.34
11.83
13.27
12.58
9.72
7.80
% Of Sales
-
1.32%
1.25%
1.19%
1.27%
1.43%
1.30%
1.73%
1.41%
1.22%
1.24%
Employee Cost
-
239.37
220.30
197.32
168.42
159.07
147.75
149.70
122.42
72.61
66.44
% Of Sales
-
12.92%
14.78%
14.34%
14.85%
15.91%
16.19%
19.51%
13.70%
9.11%
10.55%
Manufacturing Exp.
-
18.73
12.73
127.47
113.32
77.14
59.90
47.34
50.44
37.59
30.11
% Of Sales
-
1.01%
0.85%
9.26%
9.99%
7.71%
6.56%
6.17%
5.65%
4.72%
4.78%
General & Admin Exp.
-
52.58
37.74
50.67
45.52
51.03
42.51
37.52
36.01
15.35
16.13
% Of Sales
-
2.84%
2.53%
3.68%
4.01%
5.10%
4.66%
4.89%
4.03%
1.93%
2.56%
Selling & Distn. Exp.
-
102.53
119.05
33.54
32.15
68.36
49.14
27.66
29.77
34.47
27.63
% Of Sales
-
5.54%
7.99%
2.44%
2.83%
6.84%
5.38%
3.61%
3.33%
4.33%
4.39%
Miscellaneous Exp.
-
153.75
106.73
16.10
0.34
-0.01
0.05
0.00
0.00
5.67
27.63
% Of Sales
-
8.30%
7.16%
1.17%
0.03%
0.00%
0.01%
0%
0%
0.71%
0%
EBITDA
368.43
339.32
258.88
339.60
192.25
132.15
78.38
32.92
132.42
175.83
113.96
EBITDA Margin
19.21%
18.32%
17.36%
24.68%
16.95%
13.21%
8.59%
4.29%
14.82%
22.07%
18.09%
Other Income
52.91
59.31
41.85
6.69
0.33
4.62
8.47
18.85
12.72
12.23
7.28
Interest
8.91
9.13
8.45
7.99
8.75
9.66
10.22
6.78
10.16
16.05
19.13
Depreciation
54.39
51.85
44.78
36.15
26.66
22.80
26.84
30.09
28.13
16.13
15.69
PBT
358.03
337.65
247.51
302.16
157.17
104.31
49.80
14.90
106.85
155.88
86.41
Tax
82.46
72.33
60.70
63.63
36.42
23.87
14.00
3.56
24.11
43.92
12.79
Tax Rate
23.03%
21.42%
24.52%
21.06%
23.17%
22.88%
28.11%
23.89%
22.56%
28.18%
14.80%
PAT
275.58
266.31
184.56
235.94
117.02
76.46
32.94
8.83
78.51
109.39
71.90
PAT before Minority Interest
275.25
265.32
186.81
238.54
120.75
80.44
35.80
11.33
82.74
111.96
73.62
Minority Interest
-0.33
0.99
-2.25
-2.60
-3.73
-3.98
-2.86
-2.50
-4.23
-2.57
-1.72
PAT Margin
14.37%
14.38%
12.38%
17.14%
10.32%
7.65%
3.61%
1.15%
8.79%
13.73%
11.41%
PAT Growth
49.45%
44.29%
-21.78%
101.62%
53.05%
132.12%
273.05%
-88.75%
-28.23%
52.14%
 
EPS
6.08
5.88
4.07
5.21
2.58
1.69
0.73
0.19
1.73
2.41
1.59

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
1,745.16
1,202.27
886.50
636.01
542.48
470.86
433.43
454.32
379.76
142.18
Share Capital
45.32
40.93
40.93
40.93
40.93
40.93
40.93
53.43
53.43
52.03
Total Reserves
1,699.85
1,068.24
845.56
595.08
501.55
429.93
392.50
400.89
326.33
90.15
Non-Current Liabilities
93.81
57.05
23.70
24.15
17.14
15.64
16.07
-1.91
1.46
22.16
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
19.82
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
12.74
1.86
2.11
1.47
1.36
1.08
0.96
0.00
0.00
0.00
Current Liabilities
365.36
380.08
298.97
228.75
232.62
234.68
296.06
259.43
286.24
319.12
Trade Payables
230.60
200.08
168.66
110.33
106.07
77.83
161.78
118.98
107.02
83.18
Other Current Liabilities
42.20
96.80
79.69
58.86
20.90
10.08
0.71
0.68
39.88
96.58
Short Term Borrowings
41.59
41.29
18.74
18.84
99.91
117.41
109.71
87.89
82.19
105.54
Short Term Provisions
50.97
41.92
31.88
40.72
5.74
29.36
23.85
51.88
57.15
33.82
Total Liabilities
2,224.24
1,660.10
1,228.03
902.02
802.46
730.73
751.81
720.20
675.56
490.10
Net Block
486.31
428.31
309.36
302.72
269.73
279.38
266.98
269.65
165.90
145.65
Gross Block
828.26
726.26
551.92
565.39
506.26
495.35
456.49
429.47
297.78
261.70
Accumulated Depreciation
341.95
297.96
242.56
262.67
236.54
215.97
189.52
159.82
131.89
116.05
Non Current Assets
524.57
435.04
325.20
308.45
271.02
280.19
267.92
280.06
166.72
147.15
Capital Work in Progress
9.87
2.57
11.68
0.00
0.00
0.00
0.36
0.00
0.00
0.00
Non Current Investment
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
28.40
4.16
4.16
5.73
1.29
0.82
0.59
10.41
0.83
1.50
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
1,699.67
1,225.07
902.82
593.59
531.44
450.54
483.88
440.15
508.83
342.95
Current Investments
0.54
0.44
0.26
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
484.74
424.44
404.32
241.84
293.25
218.12
190.09
167.79
130.11
102.59
Sundry Debtors
416.85
394.78
271.95
243.35
176.60
176.91
247.58
217.29
183.45
169.61
Cash & Bank
714.96
349.26
212.18
93.73
33.54
39.88
25.16
35.30
185.27
46.95
Other Current Assets
82.58
24.36
14.11
11.26
28.06
15.63
21.05
19.76
10.01
23.80
Short Term Loans & Adv.
59.12
31.79
0.00
3.40
0.00
0.00
20.96
19.76
10.01
23.80
Net Current Assets
1,334.31
844.98
603.85
364.83
298.82
215.86
187.82
180.71
222.60
23.83
Total Assets
2,224.24
1,660.11
1,228.02
902.04
802.46
730.73
751.80
720.21
675.55
490.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
237.41
99.26
178.59
233.33
27.40
50.09
14.06
30.80
154.51
64.84
PBT
337.65
247.51
302.16
157.17
104.31
49.80
14.90
106.85
109.40
71.91
Adjustment
74.24
35.31
56.57
42.04
31.88
43.99
26.58
39.63
24.26
19.57
Changes in Working Capital
-111.47
-110.70
-131.61
59.12
-81.79
-36.23
-6.04
-88.14
20.27
-26.01
Cash after chg. in Working capital
300.43
172.12
227.12
258.33
54.40
57.56
35.44
58.34
153.94
65.47
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-63.01
-72.86
-48.53
-25.00
-27.00
-7.46
-21.37
-27.54
-0.89
-0.27
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-259.21
-84.39
-44.85
-59.58
-13.48
-38.81
-20.73
-123.01
-33.19
-4.49
Net Fixed Assets
-21.45
-24.09
-28.48
-23.87
-23.07
-5.86
-11.49
-22.01
-32.23
-2.62
Net Investments
-29.78
-0.18
-0.26
0.00
0.00
-1.78
-2.85
-163.82
0.00
0.00
Others
-207.98
-60.12
-16.11
-35.71
9.59
-31.17
-6.39
62.82
-0.96
-1.87
Cash from Financing Activity
197.83
79.51
-15.29
-113.55
-20.78
3.38
-3.47
-57.75
16.99
-29.28
Net Cash Inflow / Outflow
176.03
94.38
118.46
60.19
-6.86
14.67
-10.14
-149.96
138.32
31.07
Opening Cash & Equivalents
206.41
112.03
93.73
33.54
39.72
25.05
35.30
185.27
46.95
15.88
Closing Cash & Equivalent
382.44
206.41
212.18
93.73
32.85
39.72
25.16
35.30
185.27
46.95

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
38.51
27.10
21.66
15.54
13.25
11.50
10.59
10.79
8.97
3.34
ROA
13.66%
12.94%
22.40%
14.17%
10.49%
4.83%
1.54%
11.86%
19.21%
16.52%
ROE
18.59%
18.72%
31.33%
20.49%
15.88%
7.92%
2.59%
20.45%
45.15%
73.02%
ROCE
22.89%
23.82%
39.76%
25.57%
18.51%
10.60%
3.99%
23.16%
44.64%
38.30%
Fixed Asset Turnover
2.62
2.42
2.49
2.12
2.00
1.92
1.73
2.46
2.85
2.43
Receivable days
72.63
78.56
67.57
67.57
64.51
84.88
110.59
81.87
80.88
87.17
Inventory Days
81.36
97.65
84.73
86.10
93.32
81.63
85.14
60.86
53.30
52.22
Payable days
85.31
93.88
85.57
45.09
38.48
55.10
65.56
54.58
56.06
48.85
Cash Conversion Cycle
68.67
82.33
66.73
108.58
119.35
111.40
130.17
88.15
78.13
90.54
Total Debt/Equity
0.02
0.04
0.02
0.03
0.18
0.25
0.25
0.19
0.23
1.12
Interest Cover
37.99
30.31
38.84
18.97
11.80
5.87
3.20
11.52
10.72
5.52

News Update:


  • Marksans Pharma gets USFDA’s final approval for Guaifenesin Extended-Release Tablets
    22nd Aug 2023, 14:59 PM

    The company expects to launch the product immediately

    Read More
  • Marksans Pharma - Quarterly Results
    11th Aug 2023, 18:30 PM

    Read More
  • USFDA completes PADE inspection at Marksans Pharma’s Goa facility
    7th Aug 2023, 14:16 PM

    The inspection closed with two observations

    Read More
  • Marksans Pharma gets USFDA’s final approval for Acetaminophen and Ibuprofen Tablets
    12th Jul 2023, 11:57 AM

    The company plans to launch the product immediately

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.